TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02013986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etomidate
Description: 0.3mg/kg IV only once during induction of general anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: midazolam 0.1mg/kg IV only once before using of etomidate/propofol during induction of general anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam
Description: midazolam 0.1mg/kg IV only once before using of etomidate/propofol during induction of general anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: 2mg/kg IV only once during induction of general anesthesia
Study: NCT03318536

Intervention type: DRUG
Intervention: Granisetron Hydrochloride
Description: Patients received Granisetron.

Intervention type: DRUG
Intervention: No Granisetron
Description: Patients who did not receive Granisetron.
Study: NCT01693614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buparlisib
Description: 100 mg hard gelatin capsules administered orally, once daily in cycles of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buparlisib
Description: 100 mg hard gelatin capsules administered orally, once daily in cycles of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buparlisib
Description: 100 mg hard gelatin capsules administered orally, once daily in cycles of 28 days
Study: NCT01133132

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Survivorship CHESS
Description: Once the consent, baseline survey and one week accelerometer data is received by the UW research team subjects will be randomized to one of the two study conditions. Subjects will be notified of their randomization. Subjects randomized to the Survivorship CHESS condition will be offered training on the smartphone and the CHESS system. The project director (and site research coordinators) will provide training on the smartphone either in person or over the phone. Additionally, an online tutorial will be included in the Survivorship CHESS intervention for subjects to refer to as needed. Participants will then be asked to complete four surveys one baseline and then three follow up surveys.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survivorship CHESS
Description: Once the consent, baseline survey and one week accelerometer data is received by the UW research team subjects will be randomized to one of the two study conditions. Subjects will be notified of their randomization. Subjects randomized to the Survivorship CHESS condition will be offered training on the smartphone and the CHESS system. The project director (and site research coordinators) will provide training on the smartphone either in person or over the phone. Additionally, an online tutorial will be included in the Survivorship CHESS intervention for subjects to refer to as needed. Participants will then be asked to complete four surveys one baseline and then three follow up surveys.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: This person will receive usual care and a copy of the National Cancer Institute's Facing Forward booklet and the National Cancer Center Network cancer survivor toolbox.
Study: NCT02082405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given SC or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study: NCT00496028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0530
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0530
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: intravenous infusion
Study: NCT02082405

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT02485626

Intervention type: PROCEDURE
Intervention: 2D tissue doppler echocardiography
Study: NCT01779388

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: During a general anaesthesia, an evaluation will be done by conventional bronchoscopy guided by fluoroscopy and by bronchial endoscopy guided by electromagnetic navigation, the selection of order in techniques being randomly assigned.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bronchoscopy
Description: During a general anaesthesia, an evaluation will be done by conventional bronchoscopy guided by fluoroscopy and by bronchial endoscopy guided by electromagnetic navigation, the selection of order in techniques being randomly assigned.
Study: NCT02480335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosentan
Description: 62.5 mg oral twice daily for 4 weeks, then 125 mg oral twice daily.
Study: NCT02145182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Eculizumab is a complement component 5 inhibitor.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride
Study: NCT03168191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Participants will receive low dose nicotine (6 mg/ml) or high dose nicotine (12 mg/ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Participants will receive low dose nicotine (6 mg/ml) or high dose nicotine (12 mg/ml)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine
Description: Participants will receive low dose nicotine (6 mg/ml) or high dose nicotine (12 mg/ml)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Flavor
Description: Experimental fruit flavored e-cigarette for lab session

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menthol Flavor
Description: Menthol flavored e-cigarette for lab session
Study: NCT01360840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMD 525797
Description: Subjects will be administered with EMD 525797 at a dose of 1500 milligram (mg) (diluted with 0.9 percent \[%\] sodium chloride) as a 1-hour intravenous infusion every 3 Weeks until disease progression or unacceptable toxicity, whichever comes first, unless the subject stopped the trial treatment for other reasons.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMD 525797
Description: Subjects will be administered with EMD 525797 at a dose of 750 mg (diluted with 0.9% sodium chloride) as a 1-hour intravenous infusion every 3 Weeks until disease progression or unacceptable toxicity, whichever comes first, unless the subject stopped the trial treatment for other reasons.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be administered with placebo (as 0.9% sodium chloride) as a 1-hour intravenous infusion every 3 Weeks until disease progression or unacceptable toxicity, whichever comes first, unless the subject stopped the trial treatment for other reasons.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care (SoC)
Description: All the subjects followed the SoC consisting of the continued treatment with luteinizing-hormone releasing hormone agonists (or antagonists).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care (SoC)
Description: All the subjects followed the SoC consisting of the continued treatment with luteinizing-hormone releasing hormone agonists (or antagonists).
Study: NCT02023840

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metronidazole gel

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasonics

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: ultrasonics

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erythritol

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: erythritol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04299776

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CirQPOD
Description: CirQPOD is connected between the wye piece on ventilator/anesthesia machine tubing and the patient's airway and generates negative intrathoracic pressure during the expiratory phase of ventilation which has been shown to improve blood flow.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard airway management
Description: Standard airway management during surgery (PEEP of +5 cmH2O)
Study: NCT00784979

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: CMVIG
Description: 400mg/kg IV (60mg/kg/IV/hr initially, titrated up) once a week up to four weeks
Study: NCT02343965

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Touch-massage
Study: NCT04080596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dorzagliatin
Description: GKA for T2DM currently under clinical development
Study: NCT03209609

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VEST
Description: External support for vein grafts, cobalt chrome braid

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary artery bypass vein grafts
Description: Bypass coronary arteries with autologous saphenous vein grafts

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass vein grafts
Description: Bypass coronary arteries with autologous saphenous vein grafts
Study: NCT01958515

Intervention type: OTHER
Intervention: research blood draw and tissue biopsy
Description: research blood draw and tissue biopsy
Study: NCT02997878

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Orbcel-C
Description: Selected Mesenchymal Stromal Cells derived from human umbilical cord

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Orbcel-C
Description: Selected Mesenchymal Stromal Cells derived from human umbilical cord
Study: NCT04867811

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: conventional therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: conventional therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: conventional therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: conventional therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cupping therapy
Description: cupping therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: transcutaneous electrical nerve stimulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TENS and cupping therapy
Description: TENS and cupping therapy
Study: NCT02218307

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mupirocin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00934557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG Fresenius

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG Fresenius

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG Fresenius

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG Fresenius

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG Fresenius
Study: NCT05536583

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve Gastrectomy
Description: Laparoscopic sleeve Gastrectomy
Study: NCT01360840

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care (SoC)
Description: All the subjects followed the SoC consisting of the continued treatment with luteinizing-hormone releasing hormone agonists (or antagonists).
Study: NCT00016913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC=6 week one of each 4 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estramustine
Description: 2 tablets tid PO 5 of 7 days per week each 4 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 80 mg/sq m IV infusion over 1 hour weekly for ea 4 week cycle

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 77.4 Gy in 1.8 Gy fractions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide or goserelin acetate
Description: 7.5 mg IM injection once every 4 weeks for 6 months
Study: NCT04521192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: the first period: test preparation; the second period: reference preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: the first period: reference preparation the second period: test preparation
Study: NCT03999554

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LD Sing2016 M2SR H3N2 influenza vaccine
Description: This group will receive a low dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MD Sing2016 M2SR H3N2 influenza vaccine
Description: This group will receive a medium dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HD Sing2016 M2SR H3N2 influenza vaccine
Description: This group will receive a high dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally.
Study: NCT00075218

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 mg taken orally once a day. 6 week treatment cycle (Schedule 4/2) 4 weeks on study drug/2 weeks off study drug.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SU011248
Description: 50 mg taken orally once a day. 6 week treatment cycle (Schedule 4/2) 4 weeks on study drug/2 weeks off study drug.
Study: NCT04198428

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opioid Wizard
Description: The Opioid Wizard is an OUD clinical decision support tool for primary care providers to help assess, diagnose, and treat OUD in primary care (where appropriate).
Study: NCT03999554

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: LD Bris10 M2SR H3N2 influenza vaccine
Description: This group will receive a low dose of the Bris10 M2SR H3N2 monovalent influenza vaccine administered intranasally.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This group will receive saline placebo administered intranasally.
Study: NCT02008175

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Conventional CXL
Description: Crosslinking was done according to the standard protocol using hypo-osmolar riboflavin (\<0.1%) to saturate the cornea following epithelial debridement and ultra - violet light of 370nm with energy density of 3 milliwatts/cm2 with riboflavin and distilled water alternated every 2 minutes was used for the procedure..
Study: NCT04693455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD03
Description: ZD03 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD03
Description: ZD03 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD03
Description: ZD03 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD03
Description: ZD03 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD03
Description: ZD03 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD03
Description: ZD03 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD03
Description: ZD03 capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo capsule
Study: NCT03780790

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: % 0,25

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: % 0,25
Study: NCT04693455

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo capsule
Study: NCT01631110

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inflexal V
Description: Intramuscular administration (M. deltoideus) of a single dose of 0.5 mL Inflexal V

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inflexal V
Description: Intramuscular administration (M. deltoideus) of a single dose of 0.5 mL Inflexal V
Study: NCT02148159

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cachexia Acupuncture-A (Peace Classic Needles® )
Description: Acupuncture-A group will receive acupuncture in a pre-determined set of the acupuncture points.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: General Acupuncture-B (Peace Classic Needles®)
Description: Acupuncture-B group will receive acupuncture in a pre-determined set of the acupuncture points.
Study: NCT03172169

Intervention type: OTHER
Intervention: no Intervention
Description: no Intervention

Intervention type: OTHER
Intervention: no Intervention
Description: no Intervention

Intervention type: OTHER
Intervention: no Intervention
Description: no Intervention
Study: NCT03227185

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real anodal transcranial direct current stimulation (tDCS)
Description: The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used in the study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real anodal transcranial direct current stimulation (tDCS)
Description: The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used in the study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham transcranial direct current stimulation (tDCS)
Description: The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used in the study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham transcranial direct current stimulation (tDCS)
Description: The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used in the study.
Study: NCT03582878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus Oral Product
Description: Oral form of sirolimus, daily dosing to achieve target trough levels between 5-10ng/ml since 1.day of transplantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil dosing 1g before transplantation and 1g bid afterwards
Study: NCT03534362

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasopore
Description: Nasopore group will receive frontal drill out procedure as indicated with Kenalog-soaked Nasopore stent applied to the post-operative outflow tract

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Propel
Description: Propel stent group will receive frontal drill out procedure as indicated followed by Propel stent placement applied to the post-operative outflow tract.
Study: NCT03992014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linerixibat tablet
Description: Linerixibat will be available as white to slightly colored film-coated round tablet to be administered as two tablets taken in the fasted state in the morning with 240 milliliter (mL) of room temperature water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-linerixibat intravenous infusion
Description: \[14C\]-linerixibat will be available as clear, colorless solution free from visible particulates to be administered 25 mL IV over 3 hours immediately after the oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linerixibat oral solution
Description: Linerixibat will be available as clear, colorless solution free from visible particulates to be administered 60 mL solution in the fasted state in the morning.
Study: NCT01597531

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Liraglutide will be started at 0.6 mg injected subcutaneously daily for 1 week and then increased as tolerated to 1.2 mg and then a 1.8 mg daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orlistat
Description: Orlistat will be started initially at a dose of 60 mg taken with the evening meal. Additional doses will be added at breakfast or lunch every 1-2 weeks as tolerated. The patient will be advised to skip drug dosing if little or no fat is contained in the meal. Target dose will 60 mg three times a day and the patients will be advised to take a multivitamin 2 hours before or after Orlistat addition to ensure adequate nutrition.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide + Orlistat
Description: Liraglutide will be started at 0.6 mg injected subcutaneously daily for 1 week and then increased as tolerated to 1.2 mg and then a 1.8 mg daily. Patients not tolerating a higher dose will be allowed to remain on the lower dose as long they tolerate the lower. Following titration of Liraglutide to a maximum tolerated dose, Orlistat will be started initially at a dose of 60 mg taken with evening meal. Additional doses will be added at breakfast or lunch every 1-2 weeks as tolerated. The patient will be advised to skip drug dosing if little or no fat is contained in the meal. Target dose will 60 mg three times a day.
Study: NCT02047383

Intervention type: OTHER
Intervention: Respiratory infection
Description: An assessment of the patients included in the study will be conducted
Study: NCT02437383

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol ER
Description: Capsules given orally according to schedule at Visit 1, Visit 2, Visit 3, and Visit 4.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gelatin capsules with a microcrystalline cellulose filler manufactured to mimic propranolol ER 60 mg capsules
Study: NCT01842100

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Universal antibiotic prophylaxis
Description: 100 mg twice daily for 7 days starting on the day of induced abortion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Screen-and-treat
Description: Specific antibiotic treatment was only given if the women was found to have sexually transmitted infection(s) on screening.
Study: NCT01963273

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Video Assisted Ablation of Pilonidal Sinus
Study: NCT01374828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketolorac
Description: Ketorolac 30 mg in 10 ml saline will be injected at the incision sites at the conclusion of the procedure.